UConn Students for Sensible Drug Policy welcomes Will Siu, MD, DPhil and Sara Reed, MS, MFT as they discuss their participation in an FDA-approved clinical trial with MDMA – specifically their experiences as participants in the therapist training program. MDMA is commonly referred to as "molly" or "ecstacy" but substances sold by these names sometimes contain little to no MDMA.
Recent studies by the Multidisciplinary Association for Psychedelic Studies (MAPS) are demonstrating that MDMA shows great promise as a psychotherapeutic assistant in treating individuals with PTSD. Sara and Will took MDMA as part of the therapist training program in preparation for their involvement as researchers and therapists in the upcoming trials using MDMA as an adjunct to therapy for PTSD at UConn Health Center in Farmington.
This event will be held in Monteith Room 104 from 6:30-7:30pm on Tuesday, April 17th. Refreshments will be served.
fb event: https://www.facebook.com/events/539391086454418/
The event is sponsored by UConn Students for Sensible Drug Policy (SSDP), The Culture and Mental Health Disparities Psychology Lab, the Multidisciplinary Association of Psychedelic Studies (MAPS), and Collective Uplift.
You can find us on facebook at facebook.com/UConnSSDP; twitter @UConnSSDP; and instagram: uconn_ssdp
Sponsors:
Collective Uplift: https://education.uconn.edu/2015/03/13/collective-uplift-how-research-could-reshape-the-educational-experiences-of-black-male-student-athletes/
Culture and Mental Health Disparities Lab: http://www.mentalhealthdisparities.org
Multidisciplinary Association for Psychedelic Studies: maps.org
For more information, contact: UConn SDDP at uconn@chapters.ssdp.org